Related Experiment Video

Updated: Jun 3, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Novel potent pharmacological cyclin-dependent kinase inhibitors

Józefa Węsierska-Gądek1, Ivo Chamrád, Vladimír Kryštof

  • 1Cell Cycle Regulation Group, Department of Medicine, Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria. jozefa.gadek-wesierski@meduniwien.ac.at

Future Medicinal Chemistry
|March 24, 2011
PubMed

Insights

Cyclin-dependent kinases (CDKs) regulate the cell cycle. Inhibitors targeting CDKs show promise for treating cancer and neurodegenerative disorders, with many compounds in clinical trials.

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Oncology

Background:

  • Cell cycle progression relies on a balance of activating and inhibiting factors, notably cyclin-dependent kinases (CDKs).
  • Dysregulation of CDKs, including loss of inhibitors or hyperactivation, is implicated in cancer and neurodegenerative diseases.
  • Pharmacological CDK inhibitors offer potential therapeutic interventions for these conditions.

Purpose of the Study:

  • To review pharmacological CDK inhibitors that have advanced to clinical trials.
  • To highlight compounds evaluated preclinically for their therapeutic potential.
  • To discuss the rationale for using CDK inhibitors in monotherapy and combination regimens.

Main Methods:

  • Review of scientific literature on CDK inhibitors in clinical and preclinical development.
  • Analysis of compounds targeting cell cycle and transcriptional CDKs.
  • Examination of recent discoveries in cell cycle regulation.

Main Results:

  • Various classes of CDK inhibitors with diverse inhibitory profiles have been developed.
  • High selectivity and targeted activity against both cell cycle and transcriptional CDKs are of significant interest.
  • Numerous CDK inhibitors have entered clinical trials, with others undergoing preclinical evaluation.

Conclusions:

  • Pharmacological CDK inhibitors represent a promising therapeutic strategy for cell cycle-related disorders.
  • Targeted CDK inhibition holds potential for treating cancers and neurodegenerative conditions.
  • Recent advances support the clinical application of CDK inhibitors in various therapeutic settings.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.